V
Viracta Therapeutics
Viracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients
About Viracta Therapeutics
Viracta Therapeutics is a precision oncology company focused on developing innovative therapies for virus-associated malignancies, such as Epstein-Barr Virus (EBV) associated lymphomas. The company operates in the biotechnology and pharmaceutical market, primarily serving patients with viral-associated cancers and other serious diseases. Viracta's business model revolves around the research, development, and commercialization of targeted treatments. The company generates revenue through the sale of its proprietary drugs and potential licensing agreements with other pharmaceutical companies. By leveraging its expertise in oncology and virology, Viracta aims to address unmet medical needs and improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2021
News
Open roles
Viracta Therapeutics in the Encinitas ecosystem
The Viracta Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
NantKwest- FVForward Ventures
Latterell Venture Partners- WCWicklow Capital
Shenzhen Salubris Pharmaceuticals
Series B and later4 investors entered at this stage
Taiwania Capital
Oxford Finance
Standard Treasury
Silicon Valley Bank
Source: Dealroom Talent Intelligence.
Global footprint
See Viracta Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

